Gentrack Group Ltd (GTK) Gets a Sell from Jarden
Jarden analyst Guy Hooper maintained a Sell rating on Gentrack Group Ltd (GTK – Research Report) yesterday. The company's shares closed today at A$10.68.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Hooper is ranked #8960 out of 9519 analysts.
In addition to Jarden, Gentrack Group Ltd also received a Sell from UBS's Phil Campbell in a report issued on May 15. However, yesterday, UBS upgraded Gentrack Group Ltd (ASX: GTK) to a Hold.
The company has a one-year high of A$13.13 and a one-year low of A$8.53. Currently, Gentrack Group Ltd has an average volume of 198.2K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Energy Deal Creates Technical Bullish Signal for Meta Platforms Stock (META)
From a fundamental perspective, social media and technology juggernaut Meta Platforms (META) recently made a compelling case for long-term investment. Meta recently entered into a 20-year power purchase agreement with Constellation Energy's (CEG) Clinton nuclear plant in Illinois. Primarily, the deal will help Meta manage its energy costs, a core component of its forward growth strategies. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Indeed, artificial intelligence has emerged as one of the top priorities in the tech ecosystem. However, generative AI comes at a significant cost: substantial power consumption. In 2023, the power required to support AI deployment was estimated at 1 gigawatt. Experts believe that this rate will increase sevenfold to tenfold in the next two years, thus underscoring the criticality of Meta's energy deal. I too am bullish on META, but for different reasons. Market narratives aren't always reliable indicators of future valuations. Even as sentiment around Meta remains largely optimistic, analysts are actively revising their forecasts. While the majority maintain a bullish stance, the consensus price target suggests a degree of caution. For traders focused on near-term gains, compelling narratives alone don't offer enough concrete data for decision-making. In these cases, speculators often rely more on empirical, quantitative indicators to inform their strategies. When investors turn to financial publications, they're not simply looking for recycled narratives—they're in search of opportunities, specifically cases where the market may have mispriced certain stocks. To uncover these discrepancies, investors often turn to fundamental and technical analysis. While these methods can provide helpful context and short-term guidance—helping frame potential entry and exit points—they fall short of offering true empirical precision. The core issue lies in the problem of non-stationarity: over time, the metrics and benchmarks used for analysis can shift significantly due to changing market conditions and sentiment cycles, undermining their long-term reliability. For example, META stock recently closed near the $700 level. Five years ago, the equity could be bought for around $230. And a decade ago, META was priced at around $117. Attempting to conduct meaningful statistical analyses, such as price clustering, would be impossible given the significant disparity in share prices. Similarly, it's challenging to make valuation assessments on META stock. One could note that the equity trades at over 27x earnings. However, there's no first-order principle that this metric means anything. Furthermore, a range of catalysts — including business expansion, industry transitions, share dilution, and buybacks — can alter this ratio. Subsequently, comparisons across time aren't meaningful due to the shifting framework. To conduct an empirically sensible analysis, one must impose stationarity on the dataset, and that's where market breadth comes into play. At its core, market breadth is the pattern of accumulation and distribution. Another way of looking at market breadth is that it represents demand, and demand is a binary concept — it's either happening or it's not. Plus, from a statistical standpoint, demand is a discrete event that is easily categorizable and quantifiable across time. Stated differently, a market breadth profile that occurred several years ago remains relevant to the same profile that is currently in effect. That's the benefit of compressing — or abstracting to use the proper lexicon — price discovery into a binary code: analysts can develop probability matrices, focusing on how one demand profile (or behavioral state) transitions to another. With META stock, in the past two months, the security printed a '7-3-U' sequence: seven up weeks, three down weeks, with a net positive trajectory across the 10-week period. Notably, in 58.25% of cases, the following week's price action results in upside, with a median return of 2.59%. If the implications of the 7-3-U sequence materialize as projected, META stock could potentially reach $715.78 in short order, possibly within a month. Should the bulls maintain control of the market, the optimists could attempt to drive the share price to $723 over the next three weeks. Primarily, the setup incentivizes a bullish posture because of the baseline probability. On any given week, the chance that META stock will rise is 55.51%, which is a decent upward bias. However, the 7-3-U sequence adds a couple of percentage points to the odds in favor of the bullish speculator. In the open market, a 3% gain or so isn't really going to move the needle. However, with the leverage of multi-leg options strategies, relatively incremental gains can turn into significant payouts. For those who want to take a more aggressive approach while staying within the realm of rationality, the 710/715 bull call spread, expiring June 27, is offering value. This transaction involves buying the $710 call and simultaneously selling the $715 call, for a net debit paid of $210. Should META stock rise through the short strike price at expiration, the maximum reward is $290, which translates to a payout of over 138%. What makes this trade so enticing? As specified earlier, the statistical response to the 7-3-U is generally to the upside. Should META stock rise, the median return is 2.59%. Of course, the actual result could be higher or lower. If the median performance materializes, META could soon be priced near $716. Therefore, a $710 price target provides a certain level of 'safety' margin. Notably, the market makers are offering a 138% payout, which suggests that they don't expect META stock to rise significantly from here. Most likely, they believe that the good news is priced in. Among professional market analysts, META stock carries a Strong Buy consensus rating based on 42 Buys, three Holds, and one Sell rating. The average META stock price target is $698.07, implying a marginal upside potential of less than 1% over the coming 12 months. If you're looking to invest in Meta Platforms, the company's recent energy deal offers a strong long-term narrative. However, if your goal is to trade META stock for shorter-term gains, you'll need more actionable, data-driven insights. In that case, statistical analysis may be a better approach, providing the required empirical rigor to identify high-probability opportunities. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Positive Signs As Multiple Insiders Buy M3 Mining Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in M3 Mining Limited's (ASX:M3M) instance, it's good news for shareholders. While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. The insider Stephen Brockhurst made the biggest insider purchase in the last 12 months. That single transaction was for AU$285k worth of shares at a price of AU$0.069 each. That means that even when the share price was higher than AU$0.025 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels. M3 Mining insiders may have bought shares in the last year, but they didn't sell any. They paid about AU$0.05 on average. I'd consider this a positive as it suggests insiders see value at around the current price. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction! Check out our latest analysis for M3 Mining There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. M3 Mining insiders own 41% of the company, currently worth about AU$868k based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders. It doesn't really mean much that no insider has traded M3 Mining shares in the last quarter. However, our analysis of transactions over the last year is heartening. Judging from their transactions, and high insider ownership, M3 Mining insiders feel good about the company's future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing M3 Mining. Every company has risks, and we've spotted 5 warning signs for M3 Mining (of which 4 are concerning!) you should know about. Of course M3 Mining may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
